UNSPSC 51291515: Fezolamine fumarate

This classification denotes an antidepressant agent C20H23N3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I1GX0BGV7P, chemically known as win-41,528-2, but more generally known as fezolamine fumarate, which bears US NIH Compound Identifier 6435397. Most nations, for tariff and trade purposes, schedule fezolamine fumarate under HS 29331990 and SITC 51571. As of Q4 2014, FEZOLAMINE FUMARATE remains US FDA's Preferred Term for this commodity.

Fezolamine fumarate bears US NLM identifiers UMLS ID C0956920 and NCI Concept Code C72781. SMILES: CN(C)CCCN1CC(C(N1)C2CCCCC2)C3CCCCC3.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51291515 Fezolamine fumarate is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged under this code show minimal direct activity for fezolamine itself. Instead, issuing bodies are soliciting naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment programs — a broader pharmaceutical procurement landscape than the code's nominal scope suggests. State and local governments buying under this code tier include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and participating jurisdictions). These buyers are sourcing products through both direct vendor relationships and authorized wholesaler networks, with emphasis on FDA compliance, cGMP certification, and Drug Supply Chain Security Act adherence.

Recent procurement activity appears concentrated in the South and Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026; this contract requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with $5 million commercial general liability and $2 million network security insurance minimums. The code shows limited dedicated fezolamine procurement and appears to capture broader pharmaceutical sourcing across state health systems and county public health departments.